Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Active, not recruiting · NCT03158064 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Nonseminomatous germ cell tumor, dysgerminoma, germinoma, germinomatous germ cell tumor, neoplasm, seminoma | Active, not recruiting | Phase 2 | 2026-09-18 | NCT03158064 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Memorial Sloan Kettering Cancer Center | 753 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | United States | 189 |
| Memorial Sloan Kettering Bergen | Montvale | United States | 193 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Commack | Commack | United States | 189 |
| Memorial Sloan Kettering Monmouth | Middletown | United States | 206 |
| Memorial Sloan Kettering Nassau | Uniondale | United States | 193 |
| Memorial Sloan Kettering Westchester | Harrison | United States | 204 |